Clinical Trial Update: A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for camizestrant in estrogen receptor–positive, HER2-negative early breast cancer after at least 2 years of adjuvant endocrine the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Camizestrant

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer, Early Breast Cancer | Phase 3 | Status: RECRUITING